Loading...
•
Mar 31, 2021
Y-mAbs Q1 2021 Earnings Report
Reported positive financial results driven by DANYELZA sales and monetization of the Priority Review Voucher.
Key Takeaways
Y-mAbs reported a net income of $33.4 million for the first quarter of 2021, driven by DANYELZA sales and the monetization of the Priority Review Voucher. The company's cash balance stands at $252.3 million, positioning it well to advance its pipeline.
Net income was $33.4 million, or $0.80 per basic share and $0.75 per diluted share.
Net revenues from DANYELZA sales were $5.4 million.
Cash and cash equivalents totaled $252.3 million as of March 31, 2021.
European Marketing Authorization Application for omburtamab was submitted to the EMA in April.
Y-mAbs
Y-mAbs
Y-mAbs Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
The company is focused on advancing its pipeline and preparing for regulatory submissions.